180
Participants
Start Date
October 15, 2018
Primary Completion Date
January 30, 2020
Study Completion Date
January 7, 2021
Fasinumab
Subcutaneous (SC) every four weeks (Q4W)
Placebo
Subcutaneous (SC) every four weeks (Q4W)
Regeneron Study Site, Hartsdale
Regeneron Study Site, Woodstock
Regeneron Study Site, Jacksonville
Regeneron Study Site, Orlando
Regeneron Study Site, Miami
Regeneron Study Site, Clearwater
Regeneron Study Site, Ocoee
Regeneron Study Site, Columbus
Regeneron Study Site, Cincinnati
Regeneron Study Site, Caro
Regeneron Study Site, Chicago
Regeneron Study Site, Chicago
Regeneron Study Site, San Antonio
Regeneron Study Site, Houston
Regeneron Study Site, Houston
Regeneron Study Site, Bellaire
Regeneron Study Site, Phoenix
Regeneron Study Site, Glendale
Regeneron Study Site, Glendale
Regeneron Study Site, Tucson
Regeneron Study Site, Anaheim
Regeneron Study Site, Poznan
Regeneron Study Site, Wroclaw
Regeneron Study Site, Warsaw
Regeneron Study Site, Gdansk
Regeneron Study Site, Gdynia
Regeneron Study Site, Częstochowa
Regeneron Study Site, Katowice
Regeneron Study Site, Lodz
Regeneron Study Site, Lodz
Regeneron Study Site, London
Regeneron Study Site, Chorley
Regeneron Study Site, Corby
Regeneron Study Site, Edgbaston
Regeneron Study Site, Glasgow
Regeneron Study Site, Hardwick
Regeneron Study Site, Hexham
Regeneron Study Site, Kenilworth
Regulatory Study Site, London
Regeneron Study Site, London
Regeneron Study Site, London
Regeneron Study Site, Manchester
Regeneron Study Site, Northwood
Regeneron Study Site, Peterborough
Regeneron Study Site, Reading
Regeneron Study Site, Shipley
Regeneron Study Site, Waterloo
Teva Pharmaceutical Industries, Ltd.
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY